Compare BridgeBio Pharma Inc (BBIO) vs Veritone Inc (VERI) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Veritone (VERI) trades at $1.31, up 4.8% today, with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 revenue of $90M but missed earnings expectations with a net loss of $111M. Recent business developments include AI partnership expansions with government agencies and new redaction capabilities, while facing multiple securities class action lawsuits alleging improper revenue accounting.

Outlook remains challenging with persistent losses and negative margins, though analyst consensus shows divided sentiment with 46% buy ratings. Key risks include ongoing litigation, execution challenges in achieving profitability, and competitive pressures in the enterprise AI sector. The stock's low price presents speculative potential but requires careful risk assessment.